EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes

Jisun Oh, Oh-Bin Kwon, Sang-Wook Park, Jun-Woo Kim, Heejin Lee, Young-Kyu Kim, Eun Ji Choi, Haiyoung Jung iD, Dong Kyu Choi, Bae Jun Oh, Sang-Hyun Min

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jisun Oh und 10 weiteren Autor:innen. Beteiligte Einrichtung: New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu 41061, Republic of Korea. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Drug Evaluation, Preclinical, Cell Differentiation, Pluripotent Stem Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have emerged as a promising tool for studying cardiac physiology and drug responses. However, their use is largely limited by an immature phenotype and lack of high-throughput analytical methodology. In this study, we developed a high-throughput testing platform utilizing hPSC-CMs to assess the cardiotoxicity and effectiveness of drugs. Following an optimized differentiation and maturation protocol, hPSC-CMs exhibited mature CM morphology, phenotype, and functionality, making them suitable for drug testing applications. We monitored intracellular calcium dynamics using calcium imaging techniques to measure spontaneous calcium oscillations in hPSC-CMs in the presence or absence of test compounds. For the cardiotoxicity test, hPSC-CMs were treated with various compounds, and calcium flux was measured to evaluate their effects on calcium dynamics. We found that cardiotoxic drugs withdrawn due to adverse drug reactions, including encainide, mibefradil, and cetirizine, exhibited toxicity in hPSC-CMs but not in HEK293-hERG cells. Additionally, in the effectiveness test, hPSC-CMs were exposed to ATX-II, a sodium current inducer for mimicking long QT syndrome type 3, followed by exposure to test compounds. The observed changes in calcium dynamics following drug exposure demonstrated the utility of hPSC-CMs as a versatile model system for assessing both cardiotoxicity and drug efficacy. Overall, our findings highlight the potential of hPSC-CMs in advancing drug discovery and development, which offer a physiologically relevant platform for the preclinical screening of novel therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacDrug Evaluation, PreclinicalCell DifferentiationPluripotent Stem CellsHumansCardiovascular AgentsCalciumCardiotoxicityHigh-Throughput Screening AssaysHEK293 CellsCalcium Signaling

Stichwörter der Autor:innen

cardiomyocytescardiovascular pharmacologydrug screeninghigh-throughput assayshuman pluripotent stem cells

Substanzen

Cardiovascular AgentsCalcium

Autor:innen und Institutionen

  • New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI Hub), Daegu 41061, Republic of Korea.
  • Department of Oral Biochemistry, School of Dentistry, Chonnam National University, Gwangju 61186, Republic of Korea.
  • Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
  • Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.
  • Department of Functional Genomics, Korea University of Science and Technology (UST), Daejeon 34113, Republic of Korea.
  • School of Life Science and Biotechnology, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Republic of Korea.

ORCID-Profile: Haiyoung Jung

Förderung

  • National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)

Zitieren

APA

Oh, J., Kwon, O. B., Park, S. W., Kim, J. W., Lee, H., Kim, Y. K., Choi, E. J., Jung, H., Choi, D. K., Oh, B. J., & Min, S. H. (2024). Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147971

Vancouver

Oh J, Kwon OB, Park SW, Kim JW, Lee H, Kim YK, et al. Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147971

BibTeX
@article{Oh2024,
  author = {Oh, Jisun and Kwon, Oh-Bin and Park, Sang-Wook and Kim, Jun-Woo and Lee, Heejin and Kim, Young-Kyu and Choi, Eun Ji and Jung, Haiyoung and Choi, Dong Kyu and Oh, Bae Jun and Min, Sang-Hyun},
  title = {Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147971}
}
Kostenlos starten →